Title:
METHOD FOR PRODUCING CYCLIC SECONDARY AMINE
Document Type and Number:
WIPO Patent Application WO/2021/132637
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a method for producing a high-purity N-dealkylated cyclic secondary amine via a simple and non-turbulent method. An N-dealkylated cyclic secondary amine can be obtained by reacting a cyclic tertiary amine, in which a substituent expressed by R1-CH2- (wherein R1 is a hydrogen atom, an optionally substituted alkyl, a vinyl, a cyclopropyl, or an optionally substituted phenyl) is bonded to the nitrogen atom, and a dialkyl azodicarboxylate, and reacting a compound represented by EWG1-CH2-EWG2 (wherein EWG1 and EWG2 represent identical or different electron-accepting groups) with the reaction product thereof.
Inventors:
HIROSE MASAAKI (JP)
Application Number:
PCT/JP2020/048941
Publication Date:
July 01, 2021
Filing Date:
December 25, 2020
Export Citation:
Assignee:
NIPPON CHEMIPHAR CO (JP)
International Classes:
C07D451/02; C07D451/10; C07D451/12; C07D489/12
Domestic Patent References:
| WO2014190270A1 | 2014-11-27 | |||
| WO2013035833A1 | 2013-03-14 | |||
| WO2001023385A2 | 2001-04-05 |
Foreign References:
| US20090137809A1 | 2009-05-28 |
Other References:
GREEDY, B. M. ET AL.: "Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 8, 2013, pages 3207 - 3216, XP055111137, DOI: 10.1021/jm301543e
BALSSA, F. ET AL.: "Syntheses of deuterium labelled atropine and scopolamine", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 52, no. 7, 2009, pages 269 - 272, XP055838366, DOI: 10.1002/jlcr.1593
BALSSA, F. ET AL.: "Syntheses of deuterium labelled atropine and scopolamine", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 52, no. 7, 2009, pages 269 - 272, XP055838366, DOI: 10.1002/jlcr.1593
Attorney, Agent or Firm:
TAKASHIMA, Hajime (JP)
Download PDF:
Previous Patent: CANCER TREATMENT METHOD AND MEDICINE
Next Patent: IL-36R SIGNAL-SPECIFIC INHIBITORY ANTIBODY
Next Patent: IL-36R SIGNAL-SPECIFIC INHIBITORY ANTIBODY